Welcome : Guest

Cost Containment Measures from Pharma Companies to Drive the Pharmaceutical Contract Manufacturing Market

Published: January 2017


  • Code: MCP-1535
  • Pages: 347
  • Tables: 60
  • Companies: 112


The global market for Pharmaceutical Contract Manufacturing is projected to reach US$25.3 billion by 2022, driven by the growing focus on cost containment as pharmaceutical companies face shrinking profit margins as a result of growing competition from generics and biosimilars, patent expiry of blockbuster drugs and the ensuing aggravation of pricing pressures and the competitive need to increase time-to-market through resource management. Increasing number of specialized and orphan drugs are leading to fewer high-volume drugs, in turn resulting in small batch productions and small-volume contracts for contract manufacturing organizations (CMOs). Another trend in the market is the growing complexity of new drugs under development, particularly those focusing on using high potency API (HPAPIS) and addressing poor water solubility of drugs, which is compelling CMOs to acquire additional expertise and technological capabilities to remain relevant in the business and achieve growth. The United States represents the largest market worldwide supported by aggressive healthcare reforms, migration to value based healthcare, growing pricing pressures triggered by replacement of branded drugs with generics, increasing market for biologicals, and emergence of biosimilars. Asia-Pacific ranks as the fastest growing market with a CAGR of 8.2% through the analysis period led by the emergence of low cost Asian countries with huge talent pool as hubs for outsourced services. 

    Summary of Findings

  • Development of Advanced Chemical Entities & Growing Market for Generic Drugs Drive Growth in the Solid Dosage Forms Market
  • Migration from Vials to Flexible-bag & Pre-filled Syringes Systems to Spur Demand for Injectables Contract Manufacturing
  • Growing Adoption of Cutting-Edge Technologies to Radicalize PCM Environment
  • Rise in Quality and Cost Concerns Drives Use of the Perfusion Technology in Biopharmaceutical Production
  • Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production
  • Increasing Healthcare Expenditure to Spur Demand for Contract Manufacturing of Generics

    Timeline for Analysis

  • Market Estimates and Forecasts for 2015-2022
  • Historic Review 2009-2014

    Geographic Markets Analyzed

  • US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain and Rest of Europe), Asia-Pacific, and Rest of World

    Market Segmentation & Classification

  • Dosage Forms:
    • Injectables, Solid Dosage Forms, and Liquid & Semi-solid Dosage Forms


  • Aenova Group
  • Ajinomoto Althea, Inc.
  • Albany Molecular Research Inc.
  • Alcami Corporation
  • Baxter International, Inc.
  • Boehringer Ingelheim GmbH
  • Catalent Pharma Solutions, Inc.
  • Cobra Biologics Holding AB


  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable


1. http://news.ewmfg.com/blog/contract-manufacturing-vs.-global-manufacturing-infographic